Bristol-Myers Squibb Company Ce (CELG-RI) Stock Overview
Explore Bristol-Myers Squibb Company Ce’s financial performance, market position, analyst ratings, and future outlook.
Bristol-Myers Squibb Company Ce (CELG-RI)
Key Financials
Key Financials
Market Cap
183.8M
P/E Ratio
N/A
EPS (TTM)
N/A
ROE
0.62%
CELG-RI Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Bristol-Myers Squibb Company Ce (CELG-RI) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of C+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 41.94, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.15.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of N/A and a market capitalization of 183.8M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.